BALTIMORE, MD – Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced the launch of elio™ (empowering local insight for oncology) plasma complete, a NGS kit solution for comprehensive blood-based genomic analysis. The elio™ plasma complete kit is intended to support research in areas like biomarker discovery, therapy selection, and monitoring, and is ideal for investigating genetic mutations and genomic signatures in multiple cancer types. “We are thrilled to launch elio™ plasma complete, the third NGS kit on our elio™ platform, developed specifically to meet the growing needs of scientists researching genetic biomarkers of tumors directly from blood samples,” said Megan Bailey, Chief Executive Officer of PGDx. “This sample-to-answer solution brings a high quality, easy to use, comprehensive genomic profiling tool and the flexibility of a liquid biopsy format to the research community in a way never seen before. By launching this product, we hope to enable researchers and our biopharma partners to identify new biomarkers and develop new insights that inform new precision oncology medicine approaches and empower the fight against cancer.” From a simple blood draw, elio™ plasma complete analyzes circulating cell-free tumor DNA present in plasma for genetic alterations in cancer, eliminating the need for an invasive biopsy or tumor tissue. PGDx elio™ plasma complete evaluates even low-abundance sample DNA and processes samples using a high coverage next-generation sequencing panel of 521 genes. Through the elio™ testing platform, elio™ plasma complete also includes automated bioinformatics that supports the identification of somatic mutations within cell-free DNA with high sensitivity and specificity. The launch of elio™ plasma complete follows PGDx’s previously released elio™ tissue complete and elio™ plasma resolve products. PGDx elio™ plasma complete is currently available globally for Research Use Only (RUO).
About Personal Genome Diagnostics
Personal Genome Diagnostics (PGDx) empowers the fight against cancer by unlocking actionable information from the genome. We are committed to improving clinical insight, speed of results, and healthcare economics by delivering a portfolio of regulated tissue-based and liquid biopsy genomic products for health systems worldwide. PGDx was established by researchers from Johns Hopkins University who are pioneers in cancer genome sequencing and liquid biopsy technologies. For additional information, visit www.pgdx.com.